



Viral Safety Profile
LifeCell's Acellular Dermal Matrix Products
May 25, 2007

In order to demonstrate the safety of LifeCell's human derived products, a protocol was developed and executed to test the inactivation of a select panel of viruses through the LifeCell acellular dermal matrix process. In this study performed under Good Laboratory Practices (GLP) by an independent laboratory, the acellular dermal matrix manufacturing process which has been in effect since 1999 was evaluated for its ability to inactivate human immunodeficiency virus type 1 (HIV-1), bovine viral diarrhea virus (BVDV), pseudorabies virus (PrV), hepatitis A virus (HAV), and porcine parvovirus (PPV).

Test Virus	Reduction
HIV-1	>99.992% *
BVDV (surrogate for Hep C)	>99.997% *
PrV (surrogate for CMV, HSV-1, EBV, VZV)	>99.9995% *
Hep A	99.7%
PPV (surrogate for Human parvovirus)	99%

* Virus reduced to non-detectable levels

Summary of Viral Reduction: The LifeCell patented acellular dermal matrix processing demonstrated that HIV-1 and the surrogate for Hepatitis C virus are reduced to non-detectable levels (>99.99%). All other viruses included in the test were reduced by greater than 99%.

Prepared by:

Bill Barnhart
Vice-President, Quality